[Clinical aspects of a new, very low dose combination contraceptive].

In a multicentre trial in Yugoslavia 150 fertile women were treated during 2541 menstrual cycles with Ovoresta M, a new low-dosed combined oral contraceptive pill. Each tablet contains 0.75 mg lynestrenol and 0.0375 mg ethinyloestradiol. Evaluation of the results shows that there were no pregnancies. Irregular bleedings occurred in 8.1% of all cycles. The side effects recorded were mainly due to the fact that for 140 of the 150 participants this was the first oral contraceptive they ever used. 2 women dropped out for relevant reasons (irregular bleedings). Because of the low dosage of active ingredients the authors consider Ovoresta M a welcome supplement to the existing oral contraceptives.